Clinical Trials
24 trialsCD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
AO GENERIUM
A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients
Institute of Hematology & Blood Diseases Hospital, China
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
KK Women's and Children's Hospital
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
PA001
Hospital Universitario San Ignacio
Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT
Chinese PLA General Hospital
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies
Sheba Medical Center
ISIKOK-19
Acibadem University
CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
Wuhan Sian Medical Technology Co., Ltd
Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies
Wuhan Sian Medical Technology Co., Ltd
Study of Palbociclib in MLL-rearranged Acute Leukemias
University of Ulm
Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies
Wuhan Sian Medical Technology Co., Ltd
CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
GLIDE
Ciusss de L'Est de l'Île de Montréal
A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies
Second Affiliated Hospital of Guangzhou Medical University
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
RIT 90YEpra
Nantes University Hospital
B-cell therapy
University of Erlangen-Nürnberg Medical School
PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia
Proacta, Incorporated
Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia
Callisto Pharmaceuticals